Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06729996 · ClinicalTrials.gov registry record · Phase 2
Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus
A Phase 2 study of Diabetes Mellitus and Pancreatitis, Chronic, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 2
- Study locations
NCT06729996 is a Phase 2 study of Diabetes Mellitus and Pancreatitis, Chronic that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 40 participants, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06729996, a Phase 2 study of Diabetes Mellitus and Pancreatitis, Chronic, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate efficacy of pioglitazone (PIO) versus empagliflozin (EMPA) to improve glycemic control in people with Chronic Pancreatitis (CP) or Recurrent Acute Pancreatitis (RAP) associated with Diabetes Mellitus (DM). To evaluate mixed meal response in PIO versus EMPA group to better understand physiology of both therapies in CP-DM.
Conditions Studied
Interventions
- DRUG Pioglitazone (PIO)
- DRUG Empagliflozin (EMPA)
Study Locations (2)
Minnesota
- Mayo Clinic - Rochester
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-05-29 |
| Est. Completion | 2027-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06729996
The ClinicalTrials.gov registry entry for NCT06729996 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (98% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Pioglitazone (PIO) is the first listed.
NCT06729996 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Minnesota, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06729996 about?
NCT06729996 is a clinical study titled "Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus". The purpose of this study is to evaluate efficacy of pioglitazone (PIO) versus empagliflozin (EMPA) to improve glycemic control in people with Chronic Pancreatitis (CP) or Recurrent Acute Pancreatitis (RAP) associated with Diabetes Mellitus (DM). To evaluate mixed meal response in PIO versus EMPA gr...
What is the current status of trial NCT06729996?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-05-29. Estimated completion is 2027-05-31.
What conditions does trial NCT06729996 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Pancreatitis, Chronic, Pancreatitis, Acute.
What interventions are being tested in trial NCT06729996?
The interventions under investigation include: Pioglitazone (PIO) (DRUG), Empagliflozin (EMPA) (DRUG).
Who is sponsoring clinical trial NCT06729996?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06729996 being conducted?
This trial has 2 study locations across Minnesota, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals
RECRUITING · Phase 2
-
Effects of Ondansetron on Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus and Dyspepsia
RECRUITING · Phase 2
-
Smart Walk: A Culturally Tailored Smartphone-Delivered Physical Activity Intervention for African American Women
RECRUITING · Phase 2
-
Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years
RECRUITING · Phase 2
-
Sleep, Diabetic Retinopathy and Melatonin
RECRUITING · Phase 2
-
Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.